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a  b  s  t  r  a  c  t
The  fucogalactan  from  Agaricus  bisporus  (EFP-Ab)  obtained  on  aqueous  extraction  followed  by  puriﬁ-
cation  had  Mw 37.1  × 104 g mol−1 relative  to  a (1→6)-linked  -d-Galp  main-chain  partially  methylated
at  HO-3,  and  partially  substituted  at  O-2 by  nonreducing  end-units  of  -l-Fucp  or -d-Galp.  EFP-Ab
also  inhibited  signiﬁcantly  the  neurogenic  and  inﬂammatory  phases  of  formalin-induced  licking,  how-
ever,  the  antinociceptive  effect  was  more  pronounced  against  the inﬂammatory  phase  with  ID50 of
−1
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36.0  (25.8–50.3)  mg  kg .  In  addition,  EFP-Ab  decreased  the  lethality  induced  by CLP. Its  administra-
tion  reduced  the  late  mortality  rate  by 40%,  prevented  neutrophil  accumulation  in lungs and  markedly
decreased  iNOS  and COX-2  protein  expression  by  ileum  cells.  These  data  show  for the  ﬁrst  time  that  EFP-
Ab  has  signiﬁcant  anti-sepsis,  antinociceptive  and  anti-inﬂammatory  actions,  which  seems  to  be  related
to  the  decreased  iNOS  and  COX-2  expression.  Collectively,  the  present  results  demonstrate  that  EFP-Ab
could  constitute  an attractive  molecule  of  interest  for the development  of  new  drugs.ain
. Introduction
Mushrooms are currently evaluated for their nutritional value
nd acceptability as well as for their pharmacological properties.
he beneﬁts of mushroom compounds on different clinical con-
itions have attracted the interest of the scientiﬁc community in
he last decade in order to understand the molecular mechanisms
esponsible for their actions (Wasser, 2010). Polysaccharides and
ther mushroom compounds such as proteins, lypopolysaccha-
ides, glycoproteins and secondary metabolites have been classiﬁed
s molecules that have potent effects on the immune system
Wasser, 2010). In pursuit of such molecules, several polysac-
harides have been isolated from basidiomycetes, such as linear
r branched glucans and heterogalactans, which can contain O-
ethyl groups or a variety of side chains (Wasser, 2002; Zhang, Cui,
heung, & Wang, 2007). Most heterogalactans have a main chain
omposed of (1→6)-linked -d-Galp units with mainly fucose or
annose as substituent (Carbonero, Gracher, Komura, et al., 2008;
arbonero, Gracher, Rosa, et al., 2008; Rosado et al., 2003; Smiderle
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et al., 2008; Wasser, 2002; Zhang et al., 2007), although there are
few studies relating their detailed structure and biological activity.
Some of these polysaccharides have been evaluated as bio-
logical response modiﬁers, especially for their antitumor activity
(Moradali, Mostafavi, Ghods, & Hedjaroude, 2007; Wasser & Weis,
1999; Zhang et al., 2007). Some reports have shown that extracts
from mushrooms can have other effects, such as anti-inﬂammatory
and antinociceptive activity (Dore et al., 2007; Komura et al.,
2010; Moro et al., 2012; Queiroz et al., 2010; Ruthes, Rattmann,
Carbonero, Gorin, & Iacomini, 2012; Smiderle et al., 2006, 2008).
However, it is not possible to attribute a relation between struc-
ture and activity, because most of the investigations were carried
out using crude polysaccharide extracts (Lindequist, Niedermeyer,
& Julich, 2005; Poucheret, Fons, & Rapior, 2006). Recent studies
concerned anti-inﬂammatory and antinociceptive effects of fuco-
galactans, fucomannogalactans, and mannogalactans isolated from
Agaricus brasiliensis and Agaricus bisporus var. hortensis (Komura
et al., 2010), Lentinus edodes (Carbonero, Gracher, Komura, et al.,
2008), and Pleurotus pulmonarius (Smiderle et al., 2008), respec-
Open access under the Elsevier OA license.tively.
A. bisporus white button mushroom constitutes the bulk of
all mushrooms consumed and contains bioactive compounds that
have been shown to exhibit immunomodulating and anticancer
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roperties (Adams, Phung, Wu,  Ki, & Chen, 2008; Jeong,
oyyalamudi, & Pang, 2012; Jeong, Sundar, Jeong, Song, & Gerald,
012; Zhihong, Zhuyan, Nikbin, & Dayong, 2008), besides have
resented an effect against sepsis, possibly related to anti-
nﬂammatory potential of its polysaccharide (heterogalactan)
Ruthes et al., 2012). Until this moment, there are very few reports
ealing with the ability of mushroom polysaccharides in reduc-
ng mortality caused by sepsis in mice. Sepsis is a considerable
ealth problem and a leading cause of morbidity and mortality in
any intensive care units. It represents a state of overproduction of
ro-inﬂammatory mediators which frequently occurs after various
oxious injuries, especially bacterial infection, as a consequence of
bdominal surgery, appendicitis, perforated ulcers, or an ischemic
owel (Angus et al., 2001).
Thus, in order to compare chemical structure with biologi-
al properties of mushroom polysaccharides, another A. bisporus
ucogalactan was characterized. Its antinociceptive and anti-
nﬂammatory effects on neurogenic and inﬂammatory phases of
ormalin-induced pain, besides of activity against murine sepsis,
amely its effects on lethality, neutrophil migration and pro-
nﬂammatory proteins expression were also investigated.
.  Materials and methods
.1.  Biological material
Dried  fruiting bodies of A. bisporus (champignon de Paris)
ere provided by Makoto Yamashita Company (Miriam Harumi
amashita), Sao José dos Pinhais, State of Paraná, Brazil.
.2.  Extraction and puriﬁcation of fucogalactans
Extraction of crude polysaccharides and their puriﬁcation was
arried out as in Fig. 1A. Wiley-milled powder fruiting bodies
rom A. bisporus (100 g) were extracted with H2O at 4 ◦C for 6 h
6×; 2000 ml). The combined aq. extracts were added to excess
thanol (EtOH, 3:1, v/v) to precipitate polysaccharides, which were
ollected by centrifugation (8000 rpm at 5 ◦C for 20 min). Polysac-
haride fraction was then dissolved in H2O, dialyzed against tap
ater for 24 h to remove low-molecular-weight carbohydrates,
iving rise to a solution containing a fraction, denominated CW-
b. This was frozen and then allowed to thaw slowly (Gorin &
acomini, 1984), resulting in an insoluble fraction ICW-Ab, which
as separated by centrifugation as described above. The super-
atant fraction SCW-Ab, was treated with Fehling solution (Jones &
toodley, 1965), giving precipitated Cu2+ complex (FP-Ab), which
as separated by centrifugation. The precipitate was  neutralized
ith acetic acid (HOAc), dialyzed against tap water (48 h), deionized
ith mixed ion exchange resins, and then freeze-dried.
FP-Ab fraction was further puriﬁed by closed dialysis through a
embrane with a 100 kDa Mr cut-off (Spectra/Por® Cellulose Ester),
iving rise to a retained (RFP-Ab) and an eluted (EFP-Ab) material
Fig. 1A).
.3.  Monosaccharide composition of polysaccharides
Each polysaccharide fraction (1 mg)  was hydrolyzed with 2 M
FA at 100 ◦C for 8 h, followed by evaporation to dryness. The
esidues were successively reduced with NaBH4 (1 mg)  and acety-
ated with Ac2O-pyridine (1:1, v/v; 200 l) at 100 ◦C for 30 min
ollowing the method of Sassaki et al. (2008). The resulting alditol
cetates were analyzed by gas chromatography–mass spectrom-
try (GC–MS), using a Varian model 3300 gas chromatograph
inked to a Finnigan Ion-Trap, Model 810-R12 mass spectrome-
er. Incorporated was a DB-225 capillary column (30 m ×0.25 mm
.d.) programmed from 50 to 220 ◦C at 40 ◦C min−1, then hold, andlymers 92 (2013) 184– 191 185
the  alditol acetates identiﬁed by their typical retention times and
electron impact proﬁles.
2.4.  Determination of homogeneity of polysaccharides and their
molecular  weight (Mw)
The  homogeneity and molecular mass (Mw) of the puriﬁed
fucogalactan EFP-Ab were determined by high performance steric
exclusion chromatography (HPSEC), using a refractive index (RI)
detector. The eluent was 0.1 M NaNO3, containing 0.5 g l−1 NaN3.
The polysaccharide solutions were ﬁltered through a membrane
with 0.22 m diameter pores (Millipore). The speciﬁc refractive
index increment (dn/dc) was determined using a Waters 2410
detector, the samples being dissolved in the eluent, ﬁve increas-
ing concentrations, ranging from 0.2 to 1.0 mg  ml−1 being used to
determine the slope of the increment.
2.5. Methylation analysis of fucogalactan
Per-O-methylation of isolated polysaccharide (EFP-Ab; 10 mg)
was carried out using NaOH–Me2SO–MeI (Ciucanu & Kerek, 1984).
The process, after isolation of the products by neutralization
(HOAc), dialysis, and evaporation was repeated, and the methyla-
tion was found to be complete. The per-O-methylated derivatives
were hydrolyzed with 45% aqueous formic acid (HCO2H, 1 ml)  for
6 h at 100 ◦C, followed by NaB2H4 reduction and acetylation as
above (Section 2.3), to give a mixture of partially O-methylated
alditol acetates, which was analyzed by GC–MS using a Var-
ian model 4000 gas chromatograph, equipped with fused silica
capillary columns of CP-Sil-43CB. The injector temperature was
maintained at 220 ◦C, with the oven starting at 50 ◦C (hold 2 min)
to 90 ◦C (20 ◦C min−1, then held for 1 min), 180 ◦C (5 ◦C min−1, then
held for 2 min) and to 220 ◦C (3 ◦C min−1, then held for 5 min).
Helium was  used as carrier gas at a ﬂow rate of 1.0 ml min−1. Par-
tially O-methylated alditol acetates were identiﬁed from m/z of
their positive ions, by comparison with standards, the results being
expressed as a relative percentage of each component (Sassaki,
Gorin, Souza, Czelusniak, & Iacomini, 2005).
2.6. Nuclear magnetic resonance (NMR) spectroscopy
Mono- (13C, 1H and DEPT) and bidimensional NMR  spectra
(HMQC, COSY, and coupled HMQC) were prepared using a 400 MHz
Bruker model DRX Avance spectrometer incorporating Fourier
transform. Analyses were carried out at 70 ◦C on samples dis-
solved in D2O. Chemical shifts are expressed in ı relative to acetone
at ı 32.77 (13C) and 2.21 (1H), based on DSS (2,2-dimethyl-2-
silapentane-5-sulfonate-d6 sodium salt; ı = 0.0 for 13C and 1H).
2.7. Biological activity
2.7.1.  Experimental animals
Male Swiss mice (25–35 g) provided from Universidade Fed-
eral do Paraná (UFPR) and Universidade Federal de Santa Catarina
(UFSC) facilities were kept in a temperature controlled room
(20 ± 2 ◦C) on a 12-h light–dark cycle (light on from 6:00 h). Food
and water were freely available. The experiments were performed
after approval of the protocol by the Institutional Ethics Commit-
tee of the UFPR (sepsis model, CEUA/BIO-UFPR, protocol number
529) and the UFSC (formalin model, CEUA-UFSC, protocol num-
ber PP00682). All experiments were conducted in accordance with
the current guidelines for the care of laboratory animals and the
ethical guidelines for the investigation of experimental pain in con-
scious animals (Zimmermann, 1983). The numbers of animals and
186 A.C.  Ruthes et al. / Carbohydrate Polymers 92 (2013) 184– 191
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mig. 1. (A) Scheme of extraction and puriﬁcation of A. bisporus (Ab) fucogalactan. (B
efractive index detectors (–).
ntensities of noxious stimuli used were the minimum necessary to
emonstrate consistent effects of the drug treatments.
.7.2. Nociception induced by intraplantar injection of formalin
The  procedure used was similar to a previously described pro-
ocol (Santos & Calixto, 1997). The mice received 20 l of a 2.5%
ormalin solution (0.92% formaldehyde) in saline via an intraplantar
i.pl.) injection in the ventral surface of the right hindpaw. Ani-
als were pretreated with vehicle (saline, 10 ml  kg−1, i.p.), EFP-Ab
10, 30 and 100 mg  kg−1) or dexamethasone (0.5, 5 and 10 mg  kg−1)
0 min  before the formalin injection. Following the intraplantar
njection of formalin, the mice were immediately placed in a glass
ylinder (20 cm diameter), and the time spent licking the injected
aw was recorded with chronometer for both the early neurogenic
hase (0–5 min) and late inﬂammatory phase (15–30 min) of this
odel. These values were considered measures of nociception.
.7.3.  Procedure to induce sepsis by cecal ligation and puncture
CLP)
Mice  were randomly divided into ﬁve groups with 10
ice/group: sham-operation, CLP plus saline (10 ml  kg−1 s.c.), CLP
lus EFP-Ab (30 mg  kg−1 s.c.), CLP plus EFP-Ab (100 mg  kg−1 s.c.)
nd CLP plus dexamethasone (0.5 mg  kg−1 s.c.). Saline was used
s vehicle for dissolving the polysaccharide; and dexamethasone
as commercially purchased. It was administered 60 l of each
reatment solution, regarding the corporeal weigh of the ani-
als (∼30 g). Ketamine (80 mg  kg−1) and xylazine (20 mg  kg−1)ion proﬁle of fraction EFP-Ab determined by HPSEC using light scattering (· · ·) and
were  injected intraperitoneally to anesthetize the mice before the
surgical procedures. Polymicrobial sepsis was induced by CLP as
previously described (Rittirsch, Huber-Lang, Flierl, & Ward, 2009).
A midline incision about ∼1.5 cm was performed on the abdomen.
The cecum was carefully isolated and the distal 50% was  ligated.
The cecum was  then punctured twice with a sterile 16-gauge nee-
dle and squeezed to extrude the fecal material from the wounds.
The cecum was  replaced and the abdomen was closed in two  lay-
ers. Sham-control animals were treated identically, but no cecal
ligation or puncture was carried out. Each mouse received subcu-
taneous sterile saline injection (1 ml)  for ﬂuid resuscitation after
surgery. The mice were then placed on a heating pad until they
recovered from the anesthesia. Food and water ad libitum were
provided throughout the experiment. Survival was  monitored for
7 days, each 12 h. During this period, saline and drugs were subcu-
taneously administered daily.
In other experiments, during the surgery, mice were treated
subcutaneously with saline, EFP-Ab or dexamethasone. After 6 h
post-operation, mice were sacriﬁced. Their tissues from lungs and
small intestines (ileum) were collected and frozen for later use
to determine the myeloperoxidase (MPO) activity and iNOS and
COX-2 expression.2.7.4.  Lung MPO activity
MPO  activity, assessment measure of neutrophil inﬂux,
was determined according to established protocols (Bradley,
Priebat, Christensen, & Rothstein, 1982). Brieﬂy, lung tissue was
A.C. Ruthes et al. / Carbohydrate Polymers 92 (2013) 184– 191 187
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omogenized in 0.5 ml  of 50 mM potassium buffer pH 6.0 with
.5% hexadecyltrimethylammonium bromide, sonicated on ice, and
hen centrifuged at 14,000 rpm at 4 ◦C for 15 min. Supernatants
ere then assayed at a 1:20 dilution in reaction buffer (9.6 mM
,3,5,5-tetramethylbenzine, 150 nmol l−1 H2O2 in 50 mM potas-
ium phosphate buffer), and read at 620 nm.  Results are expressed
s change in optical density per milligram of protein (measured by
radford assay).
.7.5.  Western blot analysis
The ileum samples were washed twice with PBS and then
omogenated and lysed in extraction buffer [composition in
M: Tris/HCl 20 (pH 7.5; QBiogene), NaCl 150, Na3VO4, sodium
yrophosphate 10, NaF 20, okadaic acid 0.01 (Sigma), a tablet
f protease inhibitor (Roche) and 1% Triton X-100 (QBiogen)].
otal protein (20 g) was separated on 8% SDS–polyacrylamide
Sigma) gels at 80 V for 2 h. Isolated proteins were transferred
lectrophoretically onto polyvinylidine diﬂuoride membranes
Bio-Rad) at 100 V for 120 min. Membranes were blocked with
locking buffer containing 3% low fat milk powder, Tris-buffered
aline solution (Bio-Rad) and 0.1% Tween 20 (Sigma) (TBS-T) for
 h. Membranes were then incubated with the primary antibod-
es of either iNOS or COX-2 (dilution of 1:1000), overnight at
◦C. After washing, membranes were incubated with the sec-
ndary antibody (peroxidase-labeled anti-mouse IgG, dilution of
:5000) at room temperature for 60 min. Detection of -tubulin
roteins was used for normalization and quantiﬁcation of iNOS
nd COX-2. Prestained markers (Invitrogen) were used for molecu-
ar mass determinations. Immunoreactive bands were detected by
nhanced chemiluminescence (Bio-Rad).
.7.6. Statistical analysis
Data  are presented as means ± standard error of the mean
S.E.M.), except for the ID50 values (i.e., the dose of EFP-Ab necessary
o reduce the nociceptive response by 50% relative to the control
alue), which are reported as geometric means accompanied by
heir respective 95% conﬁdence limits. The ID50 values were deter-
ined by nonlinear regression from individual experiments using
inear regression with GraphPad software (GraphPad software, San
iego, CA, USA). Comparisons between experimental and control
roups were performed by one-way analysis of variance (ANOVA)CH2 inversion (A′), in D2O at 70 ◦C (chemical shifts are expressed in ı ppm).
followed  by Bonferroni’s or Newman–Keuls’ tests. P values less than
0.05 were considered as indicative of signiﬁcance.
3. Results and discussion
3.1.  Fucogalactans structural characterization
In order to obtain pure heteropolysaccharides from the fruiting
bodies of A. bisporus, they were submitted to aqueous extraction at
4 ◦C. The extracted polysaccharides were precipitated with excess
ethanol, obtained as sediments on ultracentrifugation, dialyzed
against tap water, and the solution freeze-dried to give CW-Ab
(55.3 g) (Fig. 1).
Fractionation and puriﬁcation of CW-Ab was carried out by
a freeze–thawing procedure, resulting in a respective cold-water
soluble SCW-Ab (43.4 g) and insoluble fraction (11.9 g). Fraction
SCW-Ab contained fucose, xylose, galactose, glucose and 3-O-
methyl-galactose (conﬁrmed by the presence of the fragments m/z
130 and 190, after hydrolysis, reduction with NaB2H4 and acet-
ylation) (Ruthes et al., 2012), but gave a heterogeneous HPSEC
elution proﬁle, so it was then treated with Fehling solution. Its
respective insoluble Cu2+ complex FP-Ab (2.1 g) was  further puri-
ﬁed by closed dialysis through a 100 kDa Mr cut-off membrane.
This procedure gave rise to a retained RFP-Ab (0.2 g) and an eluted
EFP-Ab (1.9 g) fraction, respectively (Fig. 1A). The EFP-Ab fraction
was homogeneous on HPSEC, and had Mw 37.1 × 104 g mol−1 (dn/dc
0.148 ml  g−1) (Fig. 1B).
As well as previously described for fraction RFP-Ab (Ruthes et al.,
2012), EFP-Ab also consists of a fucogalactan, composed of fucose
(11.2%), galactose (74.2%) and 3-O-methyl-galactose (14.6%).
EFP-Ab  was  submitted to methylation analysis, where GC–MS
of resulting O-methylalditol acetates showed the presence of
a branched structure, containing mainly, nonreducing end-units
of Fucp (2,3,4-Me3Fuc; 13.1%), besides the 6-O-(2,3,4-Me3Gal;
65.6%) and 2,6-di-O-substituted units (3,4-Me2Gal; 17.4%) of d-
galactopyranose. Small amounts of non-reducing end-units of Galp
(2,3,4,6-Me4Gal; 3.9%) was  also observed in the EFP-Ab fraction.
The ratio of units of Fucp: 2,6-di-O-Galp: 6-O-Galp was ∼1:1:5 for
EFP-Ab from A. bisporus. This relation was also conﬁrmed by the
integration of H-1 signals (5.10:5.06:5.01) present in the 1H NMR
spectrum (data not shown).
In order to elucidate the fucogalactan (EFP-Ab) structure, addi-
tional NMR  spectroscopy [1H, 13C and DEPT (Fig. 2A and A′,
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Table 1
1H and 13C NMR  chemical shifts [expressed as ı (ppm)] of A. bisporus fucogalactan (EFP-Ab).a
Units 1 2 3 4 5 6 O CH3
6a 6b
-Fucp-(1→
13C 103.9 72.0 71.2 74.5 69.9 18.2 – –
1H 5.10 3.85 3.84 3.85 4.20 1.27 – –
-Galp-(1→
13C 106.3 73.6 76.1 71.1 78.3 63.7 – –
1H 5.01 3.90 3.79 4.08 3.58 3.80 – –
2,6→)--Galp-(1→
13C 100.7 80.3 71.1 71.2 71.7 69.7 69.7 –
1H 5.06 3.84 4.08 4.09 4.21 3.70 4.01 –
6→)--Galp-(1→
13C 100.7 71.1 72.4 72.4 71.7 69.4 69.4 –
1H 5.01 3.84 3.89 4.03 4.21 3.72 3.93 –
13C 100.6 70.1 81.6 68.2 71.7 69.4 69.4 58.9
3.5
r
s
a
a
1
G
u
c
T
3
J
u
J
b
O
w
a
6
i
O
b
F
a
i6→)-3-O-Me--Galp-(1→ 1H 5.01 3.88 
a Assignments are based on 13C, 1H, DEPT, COSY and HMQC examination.
espectively), HMQC (Fig. 3), COSY and coupled HMQC (data not
hown)] analysis was also useful (Table 1). 13C NMR  (Fig. 2A)
nd HMQC spectrum (Fig. 3), both obtained using D2O as solvent
t 70 ◦C, have shown C-1/H-1 signals at ı 106.3/4.64, 103.9/5.10,
00.7/5.06, 100.7/5.01, 100.6/5.01, which could be attributed to -
alp, Fucp, Galp 2,6-di-O- and 6-O-substituted, and 3-O-Me-Galp
nits, respectively.
The  glycosidic conﬁguration was conﬁrmed by the coupling
onstants values JC-1/H-1 found in 1H/13C-coupled HMQC spectrum.
he nonreducing end- of Fucp and the main-chain units (Galp or
-O-Me-Galp or both) had the -conﬁguration due to respective
C-1/H-1 162.6 Hz and 172.6 Hz, while those of nonreducing end-
nits of Galp from EFP-Ab had -conﬁguration, consistent with
C-1/H-1 161.3 Hz (Perlin & Casu, 1969).
The presence of 6-O- and 2-O-substituted Galp units as indicated
y methylation analysis was conﬁrmed by NMR  spectroscopy.
-Substituted C-2 signal could be observed at ı 80.3 (Figs. 2 and 3),
hile signals of CH2 groups of the 6-O-(Galp and 3-O-Me-Galp)
nd 2,6-di-O-subst. (Galp) units of the main chain appears at ı
9.4/69.7 and 70.0, respectively, giving rise to inverted signals
n the DEPT spectrum (Fig. 2A′). The presence and position of
-methyl groups of the A. bisporus fucogalactan was conﬁrmed
y the presence of signal at ı 58.9/3.43 and ı 81.6/3.58 (C/H)
ig. 3. 1H (obs.)/13C HMQC spectrum of A. bisporus (A) fucogalactan EFP-Ab, in D2O
t 70 ◦C. Insert of CH3-6 region from Fucp units (A′) (chemical shifts are expressed
n  ı ppm).8 4.30 4.21 3.72 3.93 3.43
corresponding to OCH3 and O-substituted C-3 substituted/H-3,
respectively (Figs. 2 and 3 and Table 1).
The signals at ı 72.0/3.85, 71.2/3.84, 74.5/3.85, 69.9/4.20 and
d 18.2/1.27 could be attributed to C-2/H-2 to C-6/H-6 of Fucp
units, respectively, while those at ı 70.1/3.88, 81.6/3.58, 68.2/4.30,
71.7/4.21 and d 69.4/69.7/3.72/3.93 were from C-2/H-2 to C-6/H-
6 of 3-O-Me-Galp units (Figs. 2 and 3 and Table 1). -Galp units
also have their C-2/H-2 to C-6/H-6 signals attributed to those at
ı 73.6/3.90, 76.1/3.79, 71.1/4.08, 78.3/3.58 and 63.7/3.80, respec-
tively (Table 1).
EFP-Ab  fucogalactan analysis showed it to consist essentially of
a (1→6)-linked -d-galactopyranosyl main-chain, partially substi-
tuted at O-2 by nonreducing end-units of -l-Fucp. Although its
main chain showed to be partially O-methylated and had some
-d-Galp nonreducing end-units as substituents.
Fucogalactans similar to those now described have been iso-
lated from cultivated mycelium of Coprinus comatus (Fan et al.,
2006), fruiting bodies of Sarcodon aspratus (Mizuno et al., 2000),
Hericium erinaceus (Zhang et al., 2006), A. brasiliensis and A. bis-
porus var. Hortensis (Komura et al., 2010) and from Lactarius rufus
and A. bisporus (Ruthes et al., 2012). The fucogalactana described
in the present work shows a great similarity to the previously one
described for the same mushroom (Ruthes et al., 2012). However,
it has a lower content of nonreducing end-units of -Galp. In this
way, EFP-Ab fucogalactan now characterized appears more similar
with that from A. bisporus var. hortensis (Komura et al., 2010).
Since  A. bisporus var. hortensis represents A. bisporus when
mature, commonly known as Portobello mushroom, one may  sug-
gest that the fucogalactan as described in this paper is present in
both the young stage of the mushroom, and in its mature phase, i.e.,
its structure is not affected by A. bisporus fruiting body maturation.
3.2. Biological activities of EFP-Ab
It was  previously demonstrated that fucogalactans exhibited
protective effects against sepsis and antinociceptive and anti-
inﬂammatory activities in mice (Komura et al., 2010; Ruthes et al.,
2012). In this study, we evaluated if the fucogalactan isolated from
A. bisporus also presented these properties.
In the present study, we  demonstrated that EFP-Ab has a sig-
niﬁcant antinociceptive effect on formalin-induced pain in mice,
a classical chemical model of nociception. The results reported
here indicate that intraperitoneal administration of EFP-Ab pro-
duced signiﬁcant inhibition of both the neurogenic (0–5 min)
and inﬂammatory (15–30 min) phases of formalin-induced licking.
However, the antinociceptive effect was signiﬁcantly more pro-
nounced against the second phase of this model of pain (Fig. 4A
and B). The mean ID50 values calculated for these effects were >100
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Fig. 4. Effect of EFP-Ab (panels A and B) or dexamethasone (panels C and D) administered by intraperitoneal (i.p.) injection against formalin-induced nociception (neurogenic
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rhase, panels A and C, and second phase, panels B and D) in mice. Each group repr
C, black bars), indicates the mice treated by intraperitoneal (i.p.) injection with veh
he signiﬁcance level when compared to the control group. One way ANOVA follow
nd 36.0 (25.8–50.3) mg  kg−1 and the inhibitions observed were
9 ± 5% and 82 ± 9% at a dose of 100 mg  kg−1, for neurogenic and
nﬂammatory phases, respectively (Fig. 4A and B).
The  formalin test is a satisfactory and comprehensive model
or evaluating the antinociceptive activity of drugs. The intraplan-
ar injection of formalin activates nociceptive nerve terminals and
roduces neurogenic pain, whereas inﬂammatory pain is mediated
y a combination of peripheral input and spinal cord sensitization
Hunskaar & Hole, 1987; Tjølsen, Berge, Hunskaar, Rosland, & Hole,
992). Moreover, it has been demonstrated that the intraplantar
njection of formalin in rodents increases spinal levels of excit-
tory amino acids, PGE2, nitric oxide, tachykinin, kinins, among
ther peptides (Malmberg & Yaksh, 1995; Santos & Calixto, 1997;
antos, Vedana, & De Freitas, 1998; Tjølsen et al., 1992). Experi-
ental data indicate that formalin predominantly evokes activity
n C-ﬁbers peroxidase (Tjølsen et al., 1992), although A-ﬁbers
re thought to be responsible for fast nociceptive transmission
n the ﬁrst phase of the pain response (Julius & Basbaum, 2001).
t is notable that the nociception produced by formalin (neuro-
enic phase) is quite resistant to the majority of NSAIDs, such
s acetylsalicylic acid, indomethacin, paracetamol, and diclofenac.
owever, these drugs can dose-dependently attenuate the inﬂam-
atory phase of formalin-induced licking (Hunskaar & Hole, 1987;
almberg & Yaksh, 1992; Santos et al., 1998). Here, we  also demon-
trated that dexamethasone, a synthetic glucocorticoid, was  only
ble to signiﬁcantly inhibit (33 ± 6%) inﬂammatory pain induced
y formalin in high dose (10 mg  kg−1) (Fig. 4C and D). Thus, our
tudy provides evidence that EFP-Ab inhibited both phases of for-
alin test but was more effective against the inﬂammatory pain,
hich is different from the effect induced by dexamethasone; this
ata led us to investigate its anti-sepsis effect.
It is believed that sepsis may  lead to aberrant host inﬂammatory
esponses, causing cell injury and organ dysfunction. Furthermore, the mean of 6–8 animals and the error lines indicate the S.E.M. The control group
0 ml  kg−1) before formalin. The symbols *p < 0.05, **p < 0.01 and ***p < 0.001 denote
 the Newman–Keuls’ test.
neutrophil  inﬁltration is an important pathophysiologic alteration
associated with sepsis and these cells cause directly damage to
the tissues by releasing pro-inﬂammatory mediators, as cytokines,
superoxide-derived free radicals and lysosomal enzymes, such as
MPO, which amplify the systemic inﬂammatory response and cause
multiple organ failure (Landry & Oliver, 2001). In the present study,
a polymicrobial sepsis was induced by cecal ligation and puncture
(CLP) in mice to investigate the effects of EFP-Ab. The results of the
survival experiments are shown in Fig. 5A. Mice treated with vehi-
cle started to die between 12 h and 24 h after CLP, with a death rate
reaching 37.8% and 87.5% after 24 h and 96 h post-CLP, respectively.
The overall mortality in this group, at the end of the observation
period, was  100%, and the corresponding area under the curve was
3.720 (arbitrary units). The lethality was markedly delayed in mice
treated subcutaneously with EFP-Ab. Their areas under the curve
were increased to 9.060 and 11.160 after treating with EFP-Ab 30
and 100 mg kg−1, respectively. At the end of the study, the overall
survival in these EFP-Ab groups was 30% and 40%. Dexamethasone-
treated mice showed a signiﬁcant improvement in survival (area
under curve 10.100), with an overall survival rate of 16.7% at the end
of the observation period. No death occurred in the sham-operated
mice and its corresponding value for area under the lethality curve
was 16.800 (arbitrary units). This result could be attributable to an
anti-inﬂammatory activity, which is consistent with previous study
provided by our group (Komura et al., 2010; Ruthes et al., 2012).
As  commented above, MPO  is a lysosomal enzyme, produced by
polymorphonuclear leukocytes, and related to the production of
hypochlorous acid (powerful oxidant). For this reason, the effects
of EFP-Ab treatment on MPO  activity were also investigated. Sepsis
CLP surgery markedly increased lung tissue MPO  levels compared
with Sham group (45%) (Fig. 5B). This increasing in tissue MPO
was signiﬁcantly prevented by EFP-Ab 30 and 100 mg kg−1, with
an inhibition of 17.5% and 39.8%, respectively, vs. vehicle group.
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Fig. 5. EFP-Ab protects against sepsis-induced lethality (A), inhibits myeloperoxidase activity (B) and reduces iNOS and COX-2 tissue expression, determined by Western
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examethasone, the anti-inﬂammatory drug used as positive con-
rol, strongly inhibited the MPO  activity in lungs (42.3%). Therefore,
t was observed that EFP-Ab prevented the elevation of MPO activ-
ty, indirectly indicating reductions in both neutrophil recruitment
o lungs and in oxidative tissue damage. This is of particular rele-
ance because oxidative stress is known as a probable mechanism
or gut mucosal barrier dysfunction during sepsis condition, ampli-
ying and perpetuating the initial systemic inﬂammatory responses
Pastores, Katz, & Kvetan, 1996).
In this study, we also examined the effects of EFP-Ab on iNOS and
OX-2 expression in ileum of septic mice by immunoblotting. EFP-
b 100 mg  kg−1 decreased both iNOS and COX-2 expression by 53%
nd 54%, respectively [Fig. 5C, panels (a) and (b)]. Dexametasone
lso affected both iNOS and COX-2 expression, reducing by 74.5%
nd 71.4%, respectively. These results strongly conﬁrmed the anti-
nﬂammatory activity of EFP-Ab.
The enzymes iNOS and COX-2 are both upper expressed dur-
ng pro-inﬂammatory events including sepsis. The iNOS (inducible
itric oxide synthase), once expressed, produces high amounts of
O over long periods of time, which causes cellular damage. It is
lso associated with the septic shock, considered the main cause
f mortality among the septic patients (Landry & Oliver, 2001).
ompounds that inhibit iNOS expression or iNOS activity have anti-
nﬂammatory properties (Tinker & Wallace, 2006). In turn, COX-2 is
he inducible isoform of the cyclooxygenase enzyme that catalyzes
he production of inﬂammatory prostanoids. Systemic COX-2 is
ncreasingly recognized as an important player in sepsis-induced
nﬂammation. In fact, COX-2-deﬁcient mice are protected from
epsis-induced inﬂammation and death (Ejima et al., 2003)..  Conclusions
In conclusion, we observed that EFP-Ab presented antinoci-
eptive and anti-inﬂammatory activities against formalin-inducedOS and COX-2, respectively. Mice were subcutaneously administered EFP-Ab (30
nt means ± S.E.M. of 4–10 animals/group. *p < 0.05 and ***p < 0.001 versus vehicle;
ferroni’s test.
nociception with more pronounced effect on inﬂammatory phase.
In addition, EFP-Ab can prevent the lethality caused by polymicro-
bial sepsis in mice. This beneﬁcial effect seems to be, at least in
part, due to a reduction in neutrophil inﬁltration with consequent
protection against tissue damage, and also due to an inhibition on
iNOS and COX-2 tissue expression.
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